A Critical Appraisal Checklist for Preclinical Peptide Neuroscience

Critical appraisal in preclinical peptide neuroscience is the systematic evaluation of experimental design, methodological execution, analytical integrity, and reporting transparency. It is not an exercise in accepting published conclusions at face value, nor is it a search for isolated statistical significance. Instead, critical appraisal provides a structured way to determine how much confidence an experimental design actually justifies.

Many published studies present striking behavioral or neurochemical findings. However, a significant p-value does not reveal whether the experimental unit was correct. It does not show whether group allocation was protected from observer bias, or whether the peptide reached its intended central target.

This guide establishes an operational checklist for evaluating in vitro, ex vivo, and in vivo peptide neuroscience literature. By dissecting internal validity, statistical power, experimental unit identification, and peptide-specific pharmacological challenges, researchers can separate robust experimental signals from methodological noise.

What Distinguishes Reported Findings From True Experimental Validity in Peptide Studies?

When evaluating preclinical neuroscience papers, readers must distinguish between what an author reports and what the underlying methods permit a reader to conclude. Incomplete reporting makes an experiment difficult to appraise, but poor documentation does not automatically mean the procedure was neglected in the laboratory. Conversely, an experiment described in polished, confident prose may mask severe design flaws that undermine internal validity.

Internal validity refers to whether an observed biological difference can be credibly attributed to the peptide intervention rather than bias, confounding factors, or artifactual measurement error. Common safeguards for internal validity include randomized allocation, allocation concealment, blinded outcome assessment, and appropriate statistical models. If an investigation fails to implement these safeguards, any observed behavioral alteration or neurochemical shift might stem from handling stress, cage placement, or observer expectations. When appraising studies, researchers often consult frameworks for evaluating translational validity in preclinical literature to verify whether reported effects represent genuine biological interactions.

External validity describes whether a laboratory finding generalizes beyond the specific animal strain, age, sex, housing condition, and testing paradigm. A synthetic peptide showing neuroprotective activity in young male Sprague-Dawley rats may show no activity in aged female mice subjected to different experimental conditions. External validity cannot be assumed from a single positive publication. It requires deliberate replication across diverse models, distinct laboratory environments, and relevant biological backgrounds.

Reproducibility requires that a second experiment reaches a directionally and quantitatively compatible conclusion under equivalent causal conditions. Reproducibility is not demonstrated solely by crossing an arbitrary threshold such as p < 0.05. A genuinely reproducible effect exhibits stable effect sizes, consistent directionality, and explicit methodological reporting that allows independent laboratories to repeat the protocol exactly. These three dimensions should never be merged into a single quality score. A paper can maintain rigorous internal validity while remaining narrow in external scope, just as an exploratory study can yield novel biological hypotheses while lacking confirmatory safeguards.

How Does the Definition of an Experimental Unit Prevent Pseudoreplication?

The experimental unit is the physical entity that is independently assigned to a specific treatment condition. In peptide neuroscience, misidentifying the experimental unit is one of the most common statistical errors. When investigators treat non-independent observations as completely independent data points, they introduce pseudoreplication into their analysis.

Consider a study evaluating whether a novel neuropeptide alters dendritic spine density in mouse hippocampal slices. If five mice receive an intracerebroventricular injection of the peptide and five mice receive vehicle, the true sample size is five per group. If the investigator images ten pyramidal neurons per slice and measures fifty dendritic segments per neuron, the dataset contains thousands of observations. Analyzing each spine measurement as an independent observation inflates the apparent sample size, artificially shrinks standard errors, and creates false statistical significance.

Pseudoreplication similarly arises in behavioral neuroscience when treatment is administered at the cage or litter level. If an entire cage of rodents shares a water bottle containing a peptide formulation, the cage is the experimental unit. Treating each rodent in that cage as an independent unit ignores shared environmental variance and social hierarchies. Similarly, when testing neonatal rodent behavior following maternal peptide exposure, pups from the same litter share genetic and maternal factors.

To prevent pseudoreplication, researchers should inspect the alignment between the randomization protocol, the degrees of freedom, and the reported statistical model. When observations are nested within animals, litters, or cages, the analysis must use hierarchical methods such as mixed-effects models or nested analysis of variance. Alternatively, investigators can average repeated measures within an animal prior to testing group differences. Understanding where an experiment sits within the broader hierarchy of experimental evidence models helps prevent invalid statistical inferences from being treated as established neuroscience findings.

Why Does Statistical Power Matter When Evaluating Preclinical Neuroscience Data?

Statistical power represents the probability that an experiment will detect an effect of a specified magnitude if that effect truly exists. Inadequate statistical power diminishes the likelihood of finding real biological differences. More critically, low statistical power distorts published findings by increasing the probability that statistically significant results reflect exaggerated effect sizes.

Across neuroscience literature, historical analyses have highlighted systemic concerns regarding statistical power. Methodological reviews estimate that average statistical power across many neuroscience domains hovers around 20 percent. While this field-wide figure does not mean every peptide experiment is underpowered, it serves as a critical warning for readers reviewing preclinical literature. When studies test small cohorts without a prospective power calculation, any significant finding is vulnerable to the phenomenon known as the winner's curse. In this scenario, only unusually large random variations cross the significance threshold, producing inflated effect sizes that cannot be replicated.

An absolute animal count cannot demonstrate adequate power on its own. Evaluating sample size requires examining the primary biological outcome, the anticipated effect size, baseline biological variability, and the planned statistical test. Studies assessing behavioral changes in open-field or maze paradigms generally encounter substantial behavioral variability. Consequently, these behavioral models require larger cohorts than highly uniform biochemical assays, such as receptor-binding assays using purified cell membranes.

Authors should report prospective sample size rationales based on explicit assumptions before conducting the experiment. Post-hoc power calculations performed after data collection provide no useful information about design adequacy, as they are direct transformations of the achieved p-value. When an experimental report lacks an a priori power calculation, readers should treat small sample sizes as exploratory observations rather than confirmatory proof.

How Do Randomization and Blinding Protect Against Systematic Bias?

Randomization and blinding are foundational protections against systematic bias in laboratory experiments. Despite their importance, systematic surveys of preclinical literature demonstrate that these safeguards are frequently omitted or underreported. Historical surveys of hundreds of animal studies revealed that fewer than 15 percent reported randomized group allocation, and fewer than 15 percent documented blinded outcome assessment. While contemporary adherence to reporting standards has improved, adherence remains uneven across biological journals.

Random sequence generation and allocation concealment represent distinct methodological protections. Random sequence generation ensures that every experimental subject possesses an equal probability of entering any group, preventing deliberate selection bias. Allocation concealment ensures that the investigator cannot foresee the upcoming group assignment during subject recruitment or enrollment. Writing that animals were randomized is insufficient. An informative report details the exact mechanism, such as computer-generated random number lists or block randomization protocols.

Confounding factors can subtly distort neuroscience experiments if environmental variables align with treatment groups. Factors such as time of day, testing order, cage location on a rack, and experimenter identity introduce systematic variation. If all vehicle-treated animals undergo behavioral testing in the morning while peptide-treated animals undergo testing in the afternoon, circadian shifts in motor activity will confound the behavioral outcome. Robust experimental protocols randomize testing order and counterbalance cage placement across holding racks to prevent systematic bias.

Blinding must be evaluated across multiple phases of an investigation. Reporting that an experiment was blinded fails to clarify who was masked and when the masking occurred:

Allocation masking: The experimenter assigning animals does not know the upcoming group assignment.
Experimental conduct: Animal caretakers and dosing personnel do not know which animals receive active peptide versus vehicle.
Outcome assessment: Observers scoring behavioral footage, quantifying histological sections, or setting signal thresholds remain masked to group identity.
Data analysis: The statistician analyzes blinded datasets using coded group designations until analytical scripts are locked.

Subjective behavioral assessments are particularly vulnerable to observer bias. Scoring freezing behavior during fear conditioning, tracking social interactions, or assessing motor deficits requires subjective interpretation. Even automated tracking software requires manual thresholding, calibration, and exclusion criteria, which can reintroduce observer bias if applied without masking.

How Should Researchers Appraise Peptide Identity, Dosing, and Central Exposure?

Peptide compounds introduce distinct biochemical and pharmacokinetic complexities that do not apply to conventional small molecules. A publication cannot establish rigorous conclusions if it describes an intervention merely by an informal name or an unverified sequence. Interpreting central nervous system effects requires verifiable peptide chemistry, analytical documentation, and pharmacokinetic confirmation.

Appraising a preclinical peptide paper requires inspecting the material's analytical provenance. Authors should state the precise amino acid sequence, terminal modifications such as N-terminal acetylation or C-terminal amidation, salt forms, and chemical purity. Peptides synthesized without rigorous quality control can contain truncated sequences, deletion fragments, residual scavenger molecules, and trifluoroacetic acid counterions. Readers should consult documentation principles for verifying analytical documentation and purity records to understand how chromatographic assays confirm identity before evaluating biological outcomes.

Analytical records, such as high-performance liquid chromatography and mass spectrometry traces, establish the chemical identity and purity of the specific batch submitted for testing. However, an analytical report cannot confirm the stability of the peptide once reconstituted in vehicle or stored under specific laboratory conditions. Peptides are vulnerable to aggregation, oxidation, enzymatic degradation, and surface adsorption to plastic tubes. An experimental protocol should state the vehicle composition, reconstitution technique, storage temperature, and duration before administration.

Dosing descriptions require standardization to permit comparison across literature. Studies should report both the total absolute dose administered and the normalized dose per unit of body weight. Describing an injection merely as ten micrograms leaves the reader unable to determine whether young or mature animals received the compound. Furthermore, the route of administration dictates systemic bioavailability and central exposure:

Intracerebroventricular or intraparenchymal injection: Bypasses the blood-brain barrier to deliver peptide directly into cerebrospinal fluid or parenchyma, but introduces surgical trauma and non-physiological local concentrations.
Intranasal delivery: Frequently cited as a non-invasive conduit to bypass the blood-brain barrier via olfactory and trigeminal nerve pathways. However, peripheral absorption into the bloodstream remains substantial, making central targeting claims uncertain without local pharmacokinetic tracing.
Systemic administration via intravenous, subcutaneous, or intraperitoneal routes: Requires proof that the intact peptide crosses the blood-brain barrier in biologically meaningful quantities rather than eliciting central effects through peripheral receptor pathways.

A documented behavioral change following peripheral peptide administration does not prove central target engagement. Peripheral receptor activation can signal the central nervous system through vagal afferents or altered systemic cytokine levels. Without direct central pharmacokinetic measurements, receptor occupancy studies, or selective central antagonists, claims of direct central action remain speculative.

Receptor cross-reactivity represents an additional pharmacological hurdle in peptide neuroscience. Oxytocin and arginine vasopressin provide a classic illustration of target ambiguity. Both peptides share structural homology and display functional cross-reactivity across oxytocin receptors and vasopressin V1a, V1b, and V2 receptors. In rodent models, high concentrations of oxytocin can activate vasopressin receptors, and vasopressin can engage oxytocin pathways. When an experiment reports that an oxytocin analogue alters social interaction or anxiety-like behavior, that behavioral shift does not prove selective oxytocin receptor mediation. Confirmatory pharmacology requires selective antagonists, receptor knockout models, or direct binding assays to substantiate mechanistic claims.

What Does a Systematic Step-by-Step Critical Appraisal Checklist Look Like?

To systematically evaluate preclinical peptide neuroscience research, teams can utilize a structured checklist based on the ARRIVE 2.0 guidelines. The checklist covers design, sample size, animal flow, allocation, blinding, statistical modeling, peptide chemistry, and data reporting.

Preclinical Peptide Appraisal Checklist Structure
1. Research Question & Design - Hypotheses, comparators, controls, experimental units.
1. Sample Size & Animal Flow - Power calculations, inclusion/exclusion, attrition tracking.
1. Allocation & Bias Control - Randomization methods, allocation concealment, confounder management.
1. Masking & Blinding - Blinding across conduct, assessment, and statistical analysis.
1. Outcomes & Statistics - Prespecified endpoints, hierarchical models, effect sizes.
1. Peptide Characterization - Sequence, purity, vehicle stability, central penetration proof.
1. Reporting Transparency - Protocol registration, raw data availability, figure consistency.

1. Research Question and Study Design

Is the primary causal hypothesis explicitly stated with a directional prediction?
Are the control conditions appropriate to isolate the specific peptide effect from vehicle, injection stress, or handling artifacts?
Are positive or active comparator controls included to establish assay sensitivity?
Is the experimental design capable of testing the proposed biological mechanism rather than merely detecting downstream behavioral output?

2. Sample Size and Animal Flow

Does the publication report the exact sample size for every experimental group and analysis?
Is there an a priori sample size calculation that specifies the primary outcome, assumed effect size, biological variance, and target power?
Are criteria for including and excluding animals, experimental units, and data outliers established prospectively?
Does the animal flow balance completely across the text, tables, and figures without unexplained subject attrition?

3. Randomization and Allocation Integrity

Was treatment allocation randomized using an explicit, non-predictable method?
Was allocation concealed from investigators until treatment was administered?
Were environmental confounders, such as testing order, circadian timing, and cage location, balanced across experimental groups?
If randomization was omitted, did the authors provide a clear scientific justification and account for the resulting risk of selection bias?

4. Blinding and Observational Safeguards

Were investigators masked to group allocation during experimental execution, outcome assessment, and data analysis?
Were subjective behavioral tests scored by independent observers who had no knowledge of treatment conditions?
If automated scoring software was utilized, were tracking thresholds, calibrations, and filtering parameters defined prior to unblinding?
When complete blinding was impractical, were partial safeguards such as coded sample vials and blinded data auditing implemented?

5. Outcomes and Statistical Modeling

Was a single primary outcome clearly defined before conducting the experiments?
Were secondary and exploratory outcomes explicitly designated as hypothesis-generating?
Does the chosen statistical model account for data clustering, repeated measures, and nested experimental structures?
Are the degrees of freedom, test statistics, exact p-values, and effect sizes with confidence intervals reported rather than solitary significance markers?

6. Peptide Chemistry, Administration, and Target Engagement

Is the peptide identity comprehensively documented with sequence details, modifications, counterions, and purity verification?
Are the vehicle, reconstitution method, storage conditions, and chemical stability documented?
Does the dosing protocol specify both absolute quantities and body-weight-adjusted concentrations?
Is the chosen route of administration justified with pharmacokinetic proof of central nervous system penetration or target engagement?
Were receptor cross-reactivity and off-target pharmacological interactions evaluated using selective antagonists or genetic tools?

7. Transparency, Reporting, and Generalization

Was the experimental design, protocol, and analytical plan preregistered in an independent repository prior to data collection?
Do the published figures, graph axes, and text narratives display consistent numbers and denominators?
Are raw analytical data and statistical scripts accessible in public repositories for independent verification?
Does the discussion restrict its conclusions to the specific sex, age, strain, and model tested without unjustified extrapolation?

Reviewing experimental work through systematic checklists helps build reliable peptide compound evidence profiles across diverse publications.

What Case Patterns Reveal How Methodological Flaws Distort Peptide Claims?

Examining realistic case patterns illustrates how subtle methodological shortcomings compromise biological conclusions. The following illustrative models highlight common experimental patterns in preclinical peptide literature.

Illustrative Model 1: Nested Data and Pseudoreplication in Electrophysiology

An investigation explores whether an engineered neuropeptide modulates synaptic plasticity in hippocampal circuits. The researchers administer the peptide to four male mice and vehicle to four male mice. From each mouse, they prepare four acute hippocampal slices, recording long-term potentiation from three pyramidal cells per slice.

The authors pool the recordings into two groups: forty-eight peptide-treated neurons and forty-eight vehicle-treated neurons. A two-sample t-test yields a p-value of 0.004, and the authors conclude that the peptide enhances synaptic plasticity.

Hierarchical Data Structure (Illustrative Model 1)
Level 1: Treatment Allocation (Mice, N 4 per group) True Independent Unit
Level 2: Tissue Slices (Slices, N 4 per mouse) Clustered Unit
Level 3: Recorded Neurons (Cells, N 3 per slice) Repeated Observation

In this model, the biological unit independently assigned to treatment was the mouse, not the individual neuron. The forty-eight cellular measurements are nested within slices, which are nested within animals. Treating these clustered observations as independent creates severe pseudoreplication, inflating the statistical degrees of freedom and overestimating precision. A rigorous reanalysis would employ a linear mixed-effects model with random intercepts for mice and slices, or collapse the cellular data into mean values per animal.

Illustrative Model 2: The Mechanistic Overreach of Behavioral Findings

An experiment evaluates an intranasally administered cyclic peptide designed to target the oxytocin receptor system. Male Sprague-Dawley rats receive either the peptide or vehicle, followed by an elevated plus maze test to evaluate anxiety-like behavior. Rats receiving the peptide spend significantly more time in the open arms. The authors conclude that the novel peptide acts as a potent central oxytocin receptor agonist to alleviate anxiety.

This conclusion exceeds what the experimental design can support. First, elevated plus maze behavior reflects an exploratory phenotype that can be influenced by motor activity, olfactory stimulation, or handling stress. Second, intranasal administration does not automatically prove direct central nervous system penetration. Third, the authors performed no target-engagement assays, used no selective oxytocin antagonists, and did not examine vasopressin receptor cross-reactivity. A scientifically bounded conclusion would state that intranasal administration increased open-arm exploration, while noting that the central mechanism and receptor selectivity remain unverified.

Illustrative Model 3: Unreported Attrition and Changing Denominators

A research team investigates whether a synthetic peptide reduces infarct volume in a rodent stroke model. The methods section notes that thirty mice were randomly assigned to peptide or vehicle groups, indicating fifteen mice per group. In the results section, the infarct volume graph depicts twelve mice in the vehicle group and eight mice in the peptide group.

The text does not state why seven mice were excluded from the final analysis. If animals that died during surgery or developed massive hemorrhages were removed selectively from the peptide group, the reported reduction in average infarct volume might reflect survivor bias rather than neuroprotection. When animal flow fails to reconcile across an experiment, reader confidence in the reported effect size drops substantially.

Illustrative Model 4: Sex Bias and Broad Generalization

A study tests a neuroactive peptide in an animal model of depressive-like behavior using adult male C57BL/6J mice. The peptide produces a statistically significant reduction in immobility duration during the forced swim test. In the paper's discussion, the authors describe the peptide as a promising broad-spectrum intervention for mood disorders.

Extrapolating findings from male mice to all biological contexts ignores established neuroendocrine differences. Central peptide systems, including oxytocin, vasopressin, and corticotropin-releasing factor, exhibit pronounced sex-dependent receptor distribution and steroid hormone interactions. A finding established solely in young adult males cannot be generalized to females, aged animals, or other species without direct experimental validation.

How Can Research Teams Assign Qualitative Confidence Ratings to Preclinical Claims?

Rather than calculating a single numerical score that combines unrelated study features, research teams can apply a structured qualitative confidence rating. This rating evaluates specific scientific claims individually, recognizing that a single paper may provide strong evidence for one claim while offering weak evidence for another.

Qualitative Confidence Rating Tiers
Tier 1: Higher Confidence in Specific Claim
Predefined hypothesis, clear units, verified peptide purity, blinded.
Tier 2: Moderate Confidence with Noted Constraints
Valid design, minor reporting gaps, narrow demographic/sex scope.
Tier 3: Low Confidence or Substantial Bias Risk
Unclear units, unmasked scoring, probable pseudoreplication.
Tier 4: Uninterpretable for the Claimed Mechanism
Biological design does not isolate or test the proposed pathway.

Higher Confidence in a Specific Claim

The experimental unit is clearly identified and correctly aligned with the statistical model. Group allocation was randomized using a verified sequence generation process, and allocation concealment was documented. Outcome assessment and data analyses were conducted under blinded conditions.

The sample size was supported by an a priori power calculation, and animal flow reconciles completely without unexplained attrition. The administered peptide is fully characterized regarding sequence, counterions, and purity. In addition, claims of central target engagement are substantiated by direct pharmacokinetic or pharmacodynamic data.

Moderate Confidence With Noted Constraints

The core experimental design is sound and the observed difference is likely genuine under the specific conditions tested. However, certain reporting elements remain incomplete, such as omitting allocation concealment details or relying on partial blinding during conduct.

The sample size rationale may be retrospective rather than prospective, or the biological scope may be restricted to a single sex or strain. The findings provide solid preliminary support for the observation, but broad generalizations remain unverified.

Low Confidence or Substantial Bias Risk

The study displays critical methodological limitations that threaten internal validity. The experimental unit is ambiguously defined, suggesting probable pseudoreplication in the statistical analysis. Randomization and blinding are omitted or reported without procedural details.

Subject attrition is evident from fluctuating denominators in figures, but reasons for exclusions are absent. Peptide characterization is incomplete, lacking analytical purity data or stability verification. The reported effect may stem from bias, confounding factors, or selective reporting.

Uninterpretable for the Claimed Mechanism

The experimental design is fundamentally incapable of testing the author's primary mechanistic conclusion. For example, a behavioral change following peripheral peptide administration is attributed to a specific central receptor without pharmacokinetic verification, receptor antagonist controls, or genetic validation. While the physical measurement may be accurate, the causal explanation lacks direct empirical support.

How Do Standard Analytical Testing Methods Connect to Biological Reliability?

Methodological appraisal extends beyond animal handling to include the analytical chemistry of the experimental peptide. Laboratory testing records confirm whether the substance delivered to an animal matches the structural entity intended by the study design.

Researchers routinely review standard analytical testing methods to understand the technical boundaries of common laboratory assays. A standard Certificate of Analysis typically features two primary tests: high-performance liquid chromatography and mass spectrometry. Reversed-phase chromatography separates chemical components based on hydrophobicity, generating a purity percentage based on the relative area under chromatographic peaks. Mass spectrometry measures the mass-to-charge ratio of the compound, confirming that the molecular weight corresponds to the theoretical amino acid sequence.

Analytical Assay Scope and Boundaries
Analytical Testing Assay What It Establishes vs Cannot Establish
High-Performance Liquid Confirms chromatographic purity.
Chromatography (HPLC) Cannot distinguish optical enantiomers.
Mass Spectrometry Confirms molecular mass identity.
(MS / LC-MS) Cannot prove correct sequence order.
Net Peptide Content Analysis Measures actual peptide mass vs salts.
(Nitrogen / Amino Acid Assay) Does not guarantee biological activity.

These analytical records have clear limitations that must be understood during critical appraisal:

Area-under-the-curve purity from chromatography does not measure absolute concentration. It reflects the relative purity of light-absorbing species at a specific wavelength, often 214 or 220 nanometers.
Mass spectrometry confirms molecular mass, but standard single-quadrupole instruments cannot detect amino acid sequence inversions or distinguish between D- and L-enantiomers.
Analytical certificates describe only the specific sample vial submitted for testing. They do not demonstrate that every vial in an experimental shipment shares identical stability, net peptide content, or sterility.
Gross powder weight differs from net peptide content. Lyophilized peptides contain counterions, such as acetate or trifluoroacetate, alongside bound water. A milligram of peptide powder often contains only 700 to 800 micrograms of active peptide base.

If an investigation fails to account for net peptide content when calculating concentrations, the true experimental dose may fall 20 to 30 percent below the stated target. Furthermore, residual trifluoroacetate counterions can influence biological systems directly, altering cellular viability or electrophysiological properties in sensitive neuronal preparations. Critical appraisal requires confirming whether authors accounted for counterion presence and net peptide content when preparing solutions.

Frequently Asked Questions About Appraising Peptide Neuroscience Research

What is the difference between a primary outcome and a secondary outcome in preclinical studies?

A primary outcome is the prespecified endpoint chosen to test the main causal hypothesis and determine the required sample size before the study begins. Secondary outcomes are supplementary endpoints evaluated to provide broader context, evaluate secondary biological pathways, or generate new hypotheses.

When studies test multiple behavioral metrics, time points, and brain regions without prespecifying a primary outcome, the risk of false-positive findings escalates due to multiple statistical comparisons. If authors report several positive behavioral outcomes but omit other standard measures from the same test battery, readers should treat the results as exploratory observations that require independent confirmation.

Can a peptide produce real behavioral changes without entering the brain?

Yes. Peripheral administration of a peptide can alter behavior without the molecule crossing the blood-brain barrier. Peptides can stimulate peripheral receptors located on sensory nerve terminals, such as the vagus nerve, which transmit afferent signals to central autonomic and emotional processing centers. Peptides can also act on peripheral immune cells, altering circulating cytokine profiles that subsequently influence neuroinflammation and behavior.

Alternatively, a peptide may act on brain regions that lack a complete blood-brain barrier, such as the area postrema or the median eminence of the hypothalamus. Demonstrating a central behavioral shift following peripheral administration does not prove central penetration without direct pharmacokinetic confirmation in cerebrospinal fluid or brain parenchyma.

Why is a non-significant result not definitive proof of no biological effect?

A non-significant result (such as p > 0.05) indicates that the observed data do not provide sufficient statistical evidence to reject the null hypothesis under the chosen experimental model. It does not prove that the peptide has no biological activity. If the experiment utilized an insufficient sample size, exhibited high biological variability, or applied an insensitive measurement assay, the study was underpowered to detect a true biological difference.

A well-designed study reports effect sizes alongside confidence intervals. A confidence interval that spans zero but includes biologically meaningful effect sizes indicates an inconclusive, low-precision study, not proof that the peptide is inactive.

How does investigator preregistration improve the credibility of preclinical peptide research?

Preregistration requires researchers to document their primary hypotheses, experimental design, sample size calculations, inclusion and exclusion criteria, and planned statistical analyses in an independent registry before collecting data. This public record prevents analytical flexibility, such as changing primary endpoints after inspecting the results, stopping data collection prematurely when significance is reached, or selectively reporting only positive outcomes.

While preregistration does not guarantee that experimental execution is free from technical errors, it allows critical appraisers to distinguish planned confirmatory tests from post-hoc exploratory analyses.

Sources

Introducing / CaliLean Field Notes

A little more
perspective.

An editorial letter for curious minds. Thoughtful reading, questions worth keeping and the sources behind them.

Explore Field Notes Join the list for the first edition

Back to all resources Back to top